RESIDUAL CANCER BURDEN
DEAD

Serial Number

97205532

Owner

Delphi Diagnostics, Inc.

Attorney

Naira Simmons

First Use Date

Oct 1, 2007

Filing Date

Jan 6, 2022

Add to watchlist:

No watchlists yet
View on USPTO

RESIDUAL CANCER BURDEN Trademark

Serial Number: 97205532

RESIDUAL CANCER BURDEN is a trademark filed by Delphi Diagnostics, Inc. on January 6, 2022. The trademark is classified under Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently no longer active.

Owner Contact Info

Delphi Diagnostics, Inc. (10 trademarks)

PO Box 341449
Austin, TX 78734

Entity Type: 03

Trademark Details

Filing Date

January 6, 2022

Registration Date

Not Registered

First Use Anywhere

October 1, 2007

First Use in Commerce

October 1, 2007

Goods & Services

Providing a website via a global computer network featuring a residual cancer burden calculator

Medical testing, prediction and assessment for diagnostic, prognosis and treatment purposes in the field of cancer research and disease classification; Providing medical, assessment and prediction information to medical professionals in the field of cancer and disease classification; Providing medical information, assessment and prediction to medical professionals on sensitivities of cancers to hormones and/or hormone therapies

Medical diagnostic apparatus for assessing and predicting recurrence of cancer cells incorporating recorded operating system software

Medical and scientific research in the field of assessing and predicting recurrence cancer after treatment and diagnosis; Medical research services in the field of assessing and predicting recurrence of cancer; Providing laboratory research services in the field of assessing and predicting effectiveness of treatment and diagnosis in gene expression, namely, cancer biology; Research and development of pharmaceuticals for the assessment and prediction of effectiveness of treatment of age-related diseases and cancer; Assessment and predictions of medical diagnosis and treatment of cancer; Providing information about medical research, predictions and assessments in the field of cancer

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 2, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 2, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 2, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 25, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 27, 2023 TEME
AMENDMENT TO USE PROCESSING COMPLETE
Apr 27, 2023 AUPC
USE AMENDMENT FILED
Apr 27, 2023 IUAF
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 26, 2023 TROA
TEAS AMENDMENT OF USE RECEIVED
Apr 26, 2023 EAAU
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 14, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 31, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 31, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 31, 2023 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 15, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 15, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 15, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 20, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 20, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 23, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 23, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 23, 2022 CNRT
ASSIGNED TO EXAMINER
May 3, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2022 NWOS
NEW APPLICATION ENTERED
Jan 10, 2022 NWAP